A Phase 4 interventional study of Aricept (donepezil hydrochloride) and placebo in Mild Cognitive Impairment, sponsored by Eisai Inc.. Completed at 49 sites in United States. Open to participants aged 45 Years to 90 Years. Per ClinicalTrials.gov, last updated 2014-01-14.
Sponsored by Eisai Inc. · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing donepezil in Cognitive Dysfunction — 1 open to participants now, 1 under way, none of them phase 3. Donepezil · Cognitive Dysfunction.
Among the 25 studies testing donepezil in Cognitive Dysfunction, this one is the 8th largest by enrollment of the 24 interventional ones that give a count, is the only one that started in 2006, is one of 8 in phase 4, and was the 10th registered.
3,878 studies on the registry are indexed under Cognitive Dysfunction; 1,119 are open to participants now.
Browse Cognitive Dysfunction studies →1 of the 25 studies testing donepezil in Cognitive Dysfunction is open now. Recruiting first, the newest first:
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Ages 50–80
Donepezil: first FDA approval 1996 (ARICEPT). What it is approved for, and how studies give it, is on its page →
Of the 753 Cognitive Dysfunction studies recruiting now, 364 (48%) set no upper age limit and 143 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 45 Years to 90 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 7 · Phase 4 8
First in 1999; this study’s year is marked. 1 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 145 is above the median of 64 across 2,797 interventional studies indexed under Cognitive Dysfunction.
Median enrollment 70 across the 24 interventional studies. Of the 23 that completed or were terminated, 10 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 25 have an industry lead sponsor. The 10 most frequent:
This study is registered under Eisai Inc., one of the names counted as Eisai Co., Ltd.. Under that name alone:
Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
14 studies in Cognitive Dysfunction by Eisai Co., Ltd.: none open now, 1 under way, 1 of them phase 3. Of 13 finished, 6 (46%) have results posted.
Among the 14 studies in Cognitive Dysfunction by Eisai Co., Ltd., this one is the 8th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2006, is one of 3 in phase 4, and was the 6th registered.
Eisai Co., Ltd.’s Cognitive Dysfunction studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 25 studies testing donepezil in Cognitive Dysfunction, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eisai Co., Ltd.’s 14 in Cognitive Dysfunction:
This tab as a report to print or save as PDF → With an account.
This is a multi-center, open-label study of 28 weeks duration in subjects with Mild Cognitive Impairment who have completed the double-blind study (E2020-A001-412).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Aricept (donepezil hydrochloride)
Drug: placebo
5 mg or 10 mg of donepezil hydrochloride (Aricept) taken orally once a day.
Also known as: donepezil hydrochloride
Number of Participants With Treatment-Emergent Adverse Events
Overview of Treatment-Emergent Adverse Events and Safety Population (TEAEs)
Time frame: Baseline, Week 6, Week 12 and Week 28.
| Milestone | Donepezil | Placebo |
|---|---|---|
| Started | 68 | 77 |
| Completed | 55 | 55 |
| Not completed | 13 | 22 |
Overview of Treatment-Emergent Adverse Events and Safety Population (TEAEs)
| Participants | Donepezil | Placebo |
|---|---|---|
| Any Serious TEAE | 3 | 2 |
| Any Severe TEAE | 2 | 3 |
| Any possibly/probably drug-related TEAE | 16 | 32 |
| Any TEAE causing discontinuation of study drug. | 7 | 17 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Donepezil | — | 3/68 (4.4%) | 11/68 (16.2%) |
| Placebo | — | 2/77 (2.6%) | 20/77 (26%) |
| Event | Donepezil | Placebo |
|---|---|---|
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/68 | 0/77 |
| Pelvic FractureInjury, poisoning and procedural complications | 1/68 | 0/77 |
| Prostate CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/68 | 1/77 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/68 | 1/77 |
| Event | Donepezil | Placebo |
|---|---|---|
| DiarrheaGastrointestinal disorders | 4/68 | 12/77 |
| NauseaGastrointestinal disorders | 1/68 | 7/77 |
| Muscle SpasmsMusculoskeletal and connective tissue disorders | 6/68 | 7/77 |
| Abnormal dreamsPsychiatric disorders | 1/68 | 5/77 |
| InsomniaPsychiatric disorders | 3/68 | 5/77 |
| Age, Continuous(years) | Donepezil | Placebo | Total |
|---|---|---|---|
| Mean | 71.7 ± 8.46 | 73.4 ± 8.73 | 72.6 ± 8.62 |
| Sex: Female, Male(Participants) | Donepezil | Placebo | Total |
|---|---|---|---|
| Female | 30 | 36 | 66 |
| Male | 38 | 41 | 79 |
| Region of Enrollment(participants) | Donepezil | Placebo | Total |
|---|---|---|---|
| United States | 68 | 77 | 145 |
The record gives a start of Feb 2006, a primary completion of Sep 2007 and a completion of Sep 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2009, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Donepezil